PTC Therapeutics Inc., a South Plainfield-based biopharmaceutical firm, announced on Monday that its chief operating officer, Marcio Souza, has resigned and will be departing from the company on April 25.
“We are grateful to Marcio for the significant contributions he has made to PTC,” Stuart W. Peltz, CEO of PTC Therapeutics said. “Marcio started with PTC over six years ago and has been instrumental in helping transform the company. While Marcio has been at PTC, we have grown from a U.S. based R&D organization about to launch its first treatment, to a fully integrated global company with three commercial products and a rich pipeline of many other potential treatments for multiple rare disorders. I am appreciative of his efforts in helping us grow PTC to the next level and wish Marcio the very best in his new endeavors. While Marcio will be missed, we have a very strong organization with experienced leadership in place and we are well positioned to continue to take PTC into its next stage of development.”
Souza said: “It has been a privilege to have been part of PTC’s transformational growth. PTC has always focused on providing innovative and transformative treatments to patients and I am proud to have been part of that mission.”
